Serotonin transporter mechanisms and cardiac disease.

Serotonin (5-HT)–related mechanisms have been explored extensively for pharmaceutical development, especially with regard to antidepressants and appetite suppressants. However, pharmacological agents acting through 5-HT-related pathways have been associated with a number of significant cardiovascular adverse effects, including pulmonary hypertension,1,2 cardiac arrhythmias,2 and cardiac valve abnormalities.1–4 Evidence for a 5-HT valvulopathy has arisen from a variety of observations, including clinical,3,4 animal model,5 and cell culture investigations.6,7 Patients with carcinoid syndrome tumors,4 others treated with the diet drug combination fenfluramine-phentermine (Fen/Phen),3 and individuals treated with ergot derivatives8 have been observed to develop what is most likely a 5-HT valvulopathy with comparable heart valve pathology between these different clinical groupings. In patients with carcinoid syndrome tumors, high 5-HT levels were observed to be associated with fibrodysplasia affecting predominantly the right-side cardiac valves3; a comparable pattern of valve disease was observed in a number of reported patients treated with ergot derivatives.8 The reason for this right-side valvulopathy distribution (tricuspid and pulmonary valves) has been hypothetically attributed to pulmonary monoamine oxidase clearance of 5-HT, thereby resulting in left-side cardiac valves being exposed to relatively lower 5-HT levels1,4 despite elevated systemic 5-HT. However, a recent animal study involving daily injection of 5-HT in rats demonstrated both elevated 5-HT levels and right- and left-side valve abnormalities.5 Article p 81 The Fen/Phen valvulopathy has been reported to affect both right- and left-side cardiac valves,3 and this was hypothesized to be due in part to pulmonary monoamine oxidase inhibition by Phen, resulting in increased 5-HT exposure for left-side cardiac valves.1 However, the mechanisms responsible for the pathogenesis of the cardiac effects of 5-HT are likely linked to interactions …

[1]  B. Roth,et al.  Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated With Fenfluramine and Other Serotonergic Medications , 2000, Circulation.

[2]  J. Seward,et al.  Factors associated with progression of carcinoid heart disease. , 2003, The New England journal of medicine.

[3]  R. Califf,et al.  Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation. , 2001, The American journal of cardiology.

[4]  R. Rothman,et al.  Therapeutic and adverse actions of serotonin transporter substrates. , 2002, Pharmacology & therapeutics.

[5]  M. Hamon,et al.  Deficiency of the 5-Hydroxytryptamine Transporter Gene Leads to Cardiac Fibrosis and Valvulopathy in Mice , 2005, Circulation.

[6]  A. Serretti,et al.  The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  J. Mallet,et al.  Disruption of the nonneuronal tph1 gene demonstrates the importance of peripheral serotonin in cardiac function , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Fossmark,et al.  Long-Term Serotonin Administration Induces Heart Valve Disease in Rats , 2005, Circulation.

[9]  R. Levy,et al.  Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells. , 2002, The American journal of pathology.

[10]  R. Levy,et al.  Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells. , 2002, The American journal of pathology.

[11]  A. Fishman.  Aminorex to fen/phen: an epidemic foretold. , 1999, Circulation.

[12]  T. Ryan,et al.  Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. , 2002, American heart journal.

[13]  L. Maroteaux,et al.  Functional consequence of serotonin/5-HT2B receptor signaling in heart: role of mitochondria in transition between hypertrophy and heart failure? , 2003, Circulation.

[14]  A. Lang,et al.  Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists , 2004, Movement disorders : official journal of the Movement Disorder Society.

[15]  R. M. Lightfoot,et al.  5-Hydroxytryptamine (5HT) Receptors in the Heart Valves of Cynomolgus Monkeys and Sprague-Dawley Rats , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[16]  J. Sutcliffe,et al.  Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. , 2005, American journal of human genetics.

[17]  M. Ilbawi.  Original article: cardiovascular: invited commentaryInvited commentary , 2003 .

[18]  B. Corya,et al.  Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[19]  Emile R. Mohler,et al.  Bone Formation and Inflammation in Cardiac Valves , 2001, Circulation.

[20]  R. Levy,et al.  Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. , 2003, The Annals of thoracic surgery.